Formulations for treating or preventing mucositis
US6946118B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2000 |
| Grant date | Sep 20, 2005 |
| Priority date | — |
| Expiry date | Aug 29, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. Such compositions have the advantage of treating the entire gastro-intestinal tract since the active ingredient is not removed from the tract via absorption. Further, such compositions minimize systemic exposure and accompanying side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.